Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,554.13
(
0.45%
)
US TECH 100
29,371.20
(
0.66%
)
Dow Jones
50,633.49
(
-0.02%
)
Brent Oil
93.14
(
0.76%
)
Bitcoin
72,780.05
(
-2.81%
)
News Focus
News Focus
Post# of 257649
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 123029
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 215259

Wednesday, 12/20/2017 9:43:17 AM

Wednesday, December 20, 2017 9:43:17 AM

Post# of 257649
(ADXS)—PETX wins conditional approval for treating canine osteosarcoma:

https://finance.yahoo.com/news/aratana-therapeutics-granted-conditional-license-130500431.html

The product, AT-014, uses the listeria-based antigen delivery system developed by ADXS. (ADXS is +10% today on this news.)

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today